Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.32)
# 1,033
Out of 5,050 analysts
106
Total ratings
46.03%
Success rate
4.67%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNDA Vanda Pharmaceuticals | Maintains: Overweight | $13 → $11 | $4.40 | +150.00% | 2 | Oct 30, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Overweight | $6 | $3.62 | +65.75% | 1 | Sep 22, 2025 | |
| GOSS Gossamer Bio | Reiterates: Overweight | n/a | $2.36 | - | 1 | Sep 11, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $405 → $525 | $448.91 | +16.95% | 2 | Sep 10, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $51.46 | +74.89% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $409.47 | +17.22% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $46.69 | +17.80% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $118.84 | -32.68% | 10 | Dec 11, 2024 | |
| OMER Omeros | Reiterates: Neutral | n/a | $6.59 | - | 1 | Nov 14, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Neutral | $1,015 | $657.53 | +54.37% | 8 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 | $320.20 | +26.48% | 2 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $220 | $442.70 | -50.30% | 23 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 | $14.61 | -31.55% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6.5 | $5.63 | +15.45% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $55.12 | +30.62% | 1 | Apr 13, 2023 |
Vanda Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $4.40
Upside: +150.00%
CytomX Therapeutics
Sep 22, 2025
Initiates: Overweight
Price Target: $6
Current: $3.62
Upside: +65.75%
Gossamer Bio
Sep 11, 2025
Reiterates: Overweight
Price Target: n/a
Current: $2.36
Upside: -
United Therapeutics
Sep 10, 2025
Maintains: Overweight
Price Target: $405 → $525
Current: $448.91
Upside: +16.95%
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $51.46
Upside: +74.89%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $409.47
Upside: +17.22%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $46.69
Upside: +17.80%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $118.84
Upside: -32.68%
Omeros
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $6.59
Upside: -
Regeneron Pharmaceuticals
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $657.53
Upside: +54.37%
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $320.20
Upside: +26.48%
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $442.70
Upside: -50.30%
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $14.61
Upside: -31.55%
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $5.63
Upside: +15.45%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $55.12
Upside: +30.62%